InnoCan Pharma Corporation (CSE:INNO)

Canada flag Canada · Delayed Price · Currency is CAD
6.32
-0.91 (-12.59%)
Feb 6, 2026, 11:40 AM EST
Market Cap28.43M -52.8%
Revenue (ttm)37.64M -6.6%
Net Income-4.50M
EPS-1.01
Shares Out4.50M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume815
Average Volume1,556
Open7.15
Previous Close7.23
Day's Range6.32 - 7.15
52-Week Range6.01 - 21.00
Beta0.02
RSI37.41
Earnings DateMar 31, 2026

About InnoCan Pharma

InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments: Online Sales and Other Operations. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for e... [Read more]

Founded 2018
Employees 5
Stock Exchange Canadian Securities Exchange
Ticker Symbol INNO
Full Company Profile

Financial Performance

In 2024, InnoCan Pharma's revenue was $29.44 million, an increase of 115.55% compared to the previous year's $13.66 million. Losses were -$1.83 million, -60.98% less than in 2023.

Financial numbers in USD Financial Statements